Ethylbromazolam
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C18H15BrN4 |
| Molar mass | 367.250 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Ethylbromazolam is a benzodiazepine derivative[1] which has been sold as a designer drug.[2][3][4] It is structurally similar to bromazolam, only differing by the inclusion of an ethyl group instead of a methyl group on the triazole ring. It binds with high affinity to the benzodiazepine receptor.[5]
History
[edit]Ethylbromazolam has an extremely limited history of human usage. Very little is known about its pharmacological properties, metabolism, and potential toxicity.
It was first detected in the United Kingdom in February 2025,[6] and has subsequently been detected in New Zealand in March 2025[2] and Australia.[3][4]
References
[edit]- ^ "Ethylbromazolam". Cayman Chemicals.
- ^ a b "New benzodiazepine ethylbromazolam detected in New Zealand". High Alert. Retrieved 2025-05-26.
- ^ a b "Ethylbromazolam and bromonordiazepam found in alprazolam pill". The Know. 28 April 2025. Retrieved 2025-05-26.
- ^ a b "Novel benzodiazepine found in counterfeit Xanax pressed pill and off-white powder". Assist Plus. 27 April 2025. Retrieved 2025-05-26.
- ^ Yan GM, Hu BR (September 1986). "[Benzodiazepine derivatives: relationship between anti-convulsant activity and affinity to rabbit frontal cortical receptors]". Zhongguo Yao Li Xue Bao = Acta Pharmacologica Sinica (in Chinese). 7 (5): 389–393. PMID 3035871.
- ^ "Philtre - February 2025" (PDF). WEDINOS. February 2025. Retrieved 11 June 2025.